ReviewThe American journal of pathology2015
The role of platelet-activating factor in mesangial pathophysiology.
Review in The American journal of pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Modulating platelet-activating factor by rupatadine attenuates gentamicin-induced nephrotoxicity in rats via NF-κB/caspase-3 and Nrf2/HO-1 signaling cascades.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The Inflammatory Link of Rheumatoid Arthritis and Thrombosis: Pathogenic Molecular Circuits and Treatment Approaches.Current issues in molecular biology · 2025Review
- Impact of targeting the platelet-activating factor and its receptor in cancer treatment.Military Medical Research · 2025Review
- HSD17B13 liquid-liquid phase separation promotes leukocyte adhesion in chronic liver inflammation.Journal of molecular cell biology · 2024Article
- Exploring the multifaceted role of ginkgolides and bilobalide fromFood science and biotechnology · 2024Review
- Classes of Lipid Mediators and Their Effects on Vascular Inflammation in Atherosclerosis.International journal of molecular sciences · 2023Review
- Alkyl Glycerol Ethers as Adaptogens.Marine drugs · 2022Article
- Formalin-fixed paraffin-embedded renal biopsy tissues: an underexploited biospecimen resource for gene expression profiling in IgA nephropathy.Scientific reports · 2020Article
- Neutrophil chemoattractant receptors in health and disease: double-edged swords.Cellular & molecular immunology · 2020Review
- Lipidomics Reveals the Therapeutic Effects of EtOAc Extract ofFrontiers in pharmacology · 2020Article
- Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives.Molecules (Basel, Switzerland) · 2019Review
- The Potential Role of Dietary Platelet-Activating Factor Inhibitors in Cancer Prevention and Treatment.Advances in nutrition (Bethesda, Md.) · 2019Review
- FAR2 is associated with kidney disease in mice and humans.Physiological genomics · 2018Article
- Decoding the chemotactic signal.Journal of leukocyte biology · 2018Review
- Inflammation, not Cholesterol, Is a Cause of Chronic Disease.Nutrients · 2018Review
- Atorvastatin prevents glomerular extracellular matrix formation by interfering with the PKC signaling pathway.Molecular medicine reports · 2018Article
- Phospholipids of Animal and Marine Origin: Structure, Function, and Anti-Inflammatory Properties.Molecules (Basel, Switzerland) · 2017Review
- Signalling mechanisms in PAF-induced intestinal failure.Scientific reports · 2017Article
- Understanding the connection between platelet-activating factor, a UV-induced lipid mediator of inflammation, immune suppression and skin cancer.Progress in lipid research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Platelet-activating factor (PAF) is a powerful proinflammatory mediator that displays an exceedingly diverse spectrum of biological effects. Importantly, PAF is shown to participate in a broad range of pathologic conditions. This review focuses on the role that PAF plays specifically in the pathophysiology of the kidney, the organ that is both a source and a target of PAF. Renal mesangial cells are responsible for glomerular PAF generation and, ultimately, are the victims of its excessive production. Mesangial pathology is widely acknowledged to reflect glomerular damage, which culminates in glomerulosclerosis and proteinuria. Therefore, modulation of mesangial cell responses would offer a pathophysiology-based therapeutic approach to prevent glomerular injury. However, the currently available therapeutic modalities do not allow for targeted intervention into these processes. A more profound understanding of the mechanisms that govern PAF metabolism and signaling in mesangial cells is important, because it could facilitate the quest for improved therapies for renal patients on the basis of PAF as a drug target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.